EADV Congress 2025 Poster Presentation: Zabalafin Hydrogel – A Novel, Safe, and Effective Topical Botanical Drug That Comprehensively Addresses the Four Demons of Atopic Dermatitis

Clinical Presentations

EADV Congress 2025 Poster Presentation: Zabalafin Hydrogel – A Novel, Safe, and Effective Topical Botanical Drug That Comprehensively Addresses the Four Demons of Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics September 23, 2025, 07:30 ET CONTACTS   Corporate: Neal Koller nkoller@alphynbiologics.com (410) 690-8687   Media: Susan Thomas susan@endpointcommunications.net (619) 540-9195

2025 Integrative Dermatology Summit Poster Presentation: Zabalafin Hydrogel, A Novel Topical Botanical Drug That Addresses The Four Demons of Atopic Dermatitis

Clinical Presentations

2025 Integrative Dermatology Summit Poster Presentation: Zabalafin Hydrogel, A Novel Topical Botanical Drug That Addresses The Four Demons of Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics August 12, 2025, 07:30 ET CONTACTS   Corporate: Neal Koller nkoller@alphynbiologics.com (410) 690-8687   Media: Susan Thomas susan@endpointcommunications.net (619) 540-9195

50th Annual Society for Pediatric Dermatology Meeting Poster Presentation: Zabalafin Hydrogel, A Novel Topical Botanical Drug That Addresses The Four Demons of Atopic Dermatitis

Clinical Presentations

50th Annual Society for Pediatric Dermatology Meeting Poster Presentation: Zabalafin Hydrogel, A Novel Topical Botanical Drug That Addresses The Four Demons of Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics July 22, 2025, 07:30 ET CONTACTS   Corporate: Neal Koller nkoller@alphynbiologics.com (410) 690-8687   Media: Susan Thomas susan@endpointcommunications.net (619) 540-9195

Alphyn’s Zabalafin Hydrogel for Atopic Dermatitis Highlighted in Leading Peer-Reviewed Journal

Press Release

Alphyn’s Zabalafin Hydrogel for Atopic Dermatitis Highlighted in Leading Peer-Reviewed Journal NEWS PROVIDED BY Alphyn Biologics Jul 01, 2025, 07:30 ET Expert dermatologist panel creates new atopic dermatitis (AD) algorithm (stepped diagnosis and treatment recommendations) emphasizing need for therapeutics that address AD’s intense itch, inflammation, and the AD disease stages of Staphylococcus aureus (Staph) colonization…

2025 European Society for Pediatric Dermatology (EPSD) Poster Presentation: Phase 2 trial of topical drug zabalafin treating mild to moderate atopic dermatitis

Clinical Presentations

2025 European Society for Pediatric Dermatology (EPSD) Poster Presentation: Phase 2 trial of topical drug zabalafin treating mild to moderate atopic dermatitis, starting with infection in children and adults NEWS PROVIDED BY Alphyn Biologics May 29, 2025, 19:30 ET CONTACTS   Corporate: Neal Koller nkoller@alphynbiologics.com (410) 690-8687   Media: Susan Thomas susan@endpointcommunications.net (619) 540-9195

Alphyn Announces First Patient Dosed in CLEAR-AD1 Global Phase 2b Clinical Trial Program of Zabalafin Hydrogel for Atopic Dermatitis

Press Release

Alphyn Announces First Patient Dosed in CLEAR-AD1 Global Phase 2b Clinical Trial Program of Zabalafin Hydrogel for Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics Apr 08, 2025, 07:30 ET First topical therapeutic to directly treat the immuno-inflammatory and bacterial causes of the disease at all stages, from AD onset through infection ANNAPOLIS, Md., April 8,…

Alphyn Poster at American Academy of Dermatology Annual Meeting Highlights Potential of Zabalafin Hydrogel as Singular, Comprehensive Treatment for Atopic Dermatitis

Press Release

Alphyn Poster at American Academy of Dermatology Annual Meeting Highlights Potential of Zabalafin Hydrogel as Singular, Comprehensive Treatment for Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics Mar 10, 2025, 07:30 ET Phase 2a clinical program demonstrates safety and efficacy for all endpoints in AD with and without secondary infection ANNAPOLIS, Md. and ORLANDO, Fla., March 10, 2025 /PRNewswire/ — Alphyn,…

Alphyn Secures FDA Clearance of Investigational New Drug Application for Atopic Dermatitis Treatment

Press Release

Alphyn Secures FDA Clearance of Investigational New Drug Application for Atopic Dermatitis Treatment NEWS PROVIDED BY Alphyn Biologics Feb 19, 2025, 07:30 ET Zabalafin Hydrogel holds potential for first comprehensive AD treatment with safety and patient tolerability profile for long-term, worry-free, continuous use ANNAPOLIS, Md., Feb. 19, 2025 /PRNewswire/ — Alphyn, a clinical-stage dermatology company…

Alphyn Granted U.S. Patent Covering First-in-Class Treatment for Atopic Dermatitis

Press Release

Alphyn Granted U.S. Patent Covering First-in-Class Treatment for Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics Dec 10, 2024, 07:30 ET Patent covers compositions and methods of use of drug formulation for Zabalafin Hydrogel ANNAPOLIS, Md., Dec. 10, 2024 /PRNewswire/ —  Alphyn, a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, announced today that the U.S. Patent and…

Alphyn Biologics Announces Peer-Reviewed Paper Published in Journal of Drugs in Dermatology

Press Release

Alphyn Biologics Announces Peer-Reviewed Paper Published in Journal of Drugs in Dermatology NEWS PROVIDED BY Alphyn Biologics Nov 01, 2024, 07:30 ET Paper highlights Zabalafin Hydrogel’s potential as a single topical atopic dermatitis therapy that impacts the Staphylococcus aureus component and treats all other disease symptoms across severity levels ANNAPOLIS, Md., Nov. 1, 2024 /PRNewswire/…